Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia

Psychosomatics

Volumn 50, Issue 4, 2009, Pages 317-324

  Hoffer, Zachary S ^a   Roth, Richard L ^a   Mathews, Maju ^a,b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Friends Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CABERGOLINE; CITALOPRAM; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; RISPERIDONE; ZIPRASIDONE;

ADJUVANT THERAPY; AMENORRHEA; BIPOLAR DISORDER; BREAST DISCHARGE; CLINICAL TRIAL; DEPRESSIVE PSYCHOSIS; DOPAMINE RECEPTOR BLOCKING; DRUG DOSE INCREASE; DRUG MECHANISM; GALACTORRHEA; GYNECOMASTIA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS TUMOR; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFERTILITY; MANIA; POSTMENOPAUSE; PREMENSTRUAL SYNDROME; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; DOPAMINE ANTAGONISTS; HALOPERIDOL; HUMANS; HYPERPROLACTINEMIA; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE;

EID: 69249142661     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.50.4.317     Document Type: Review

References (39)

1. Wang PS, Walker AM, Tsuang MT, et al: Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002; 59:1147-1154 (Pubitemid 35424025)
2. Haddad PM, Wieck A: Antipsychotic-induced hyperprolactinaemia mechanisms: clinical features and management. Drugs 2004; 64:2291-2314 (Pubitemid 39388605)
3. Szarfman A, Tonning JM, Levine JG, et al: Atypical antipsychotics and pituitary tumors: a pharmaco-vigilance study. Pharmacotherapy 2006; 26:748-758 (Pubitemid 43807626)
4. Shapiro DA, Renock S, Arrington E, et al: Aripiprazole: a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28:1400-1411 (Pubitemid 41070874)
5. DeLeon A, Patel NC, Crismon ML: Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004; 26:649-666 (Pubitemid 38736956)
6. Egger M, Smith GD, Phillips AN: Meta-analysis: principles and procedures. BMJ 1997; 315:1533-1537
7. Kane JM, Carson WH, Saha AR, et al: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63:763-771
8. Keck PE Jr, Marcus R, Tourkodimitris S, et al: A placebocontrolled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160:1651-1658
9. Marder SR, McQuade RD, Stock E, et al: Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61:123-136
10. Pigott TA, Carson WH, Saha AR, et al, and the Aripiprazole Study Group: Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled, 26-week study. J Clin Psychiatry 2003; 64:1048-1056
11. Potkin SG, Saha AR, Kujawa MJ, et al: Aripiprazole: an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60:681-690
12. Mallikaarjun S, Salazar DE, Bramer SL: Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004; 44: 179-187
13. Vieta E, Bourin M, Sanchez R, et al: Effectiveness of aripiprazole vs. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005; 187: 235-242
14. Chan HY, Lin WW, Lin SK, et al: Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients, with risperidone as an active control: a randomized trial. J Clin Psychiatry 2007; 68:29-36
15. Shim JC, Shin JG, Kelly DL, et al: Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007; 164:1404-1410
16. Lee BH, Kim YK, Park SH: Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 714-717
17. Freeman B, Levy W, Gorman JM: Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. J Psychiatr Pract 2007; 3:120-124
18. Steinhagen CK: Normalization of prolactin with aripiprazole in a patient with psychotic depression and a comorbid pituitary microadenoma. Psychosomatics 2007; 48:350-351
19. Anghelescu I, Wolf J: Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. J Clin Psychiatry 2004; 65:1286-1287
20. Lin SK, Chen CK: Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: a case report. J Clin Psychiatry 2006; 67:1307
21. Wahl R, Ostroff R: Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry 2005; 162:1542-1543
22. Lorenz RA, Weinstein B: Resolution of haloperidol-induced hyperprolactinemia with aripiprazole. J Clin Psychopharmacol 2007; 27:524-525
23. Wolf J, Fiedler U: Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole. J Clin Pharm Ther 2007; 32:197-198
24. Goodnick PJ, Rodriguez L, Santana O: Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 2002; 3:1381-1391
25. Byerly M, Suppes T, Tran QV, et al: Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007; 27:639-661
26. Mendhekar DN, Andrade C: Galactorrhea with aripiprazole, Can J Psychiatry 2005; 50:243
27. Ruffatti A, Minervini L, Romano M, et al: Galactorrhea with aripiprazole. Psychother Psychosom 2005; 74:391-392
28. Dal Toso R, Sommer B, Ewert M, et al: The dopamine D2 receptor: two molecular forms generated by alternative splicing. EMBO J 1989; 8:4025-4034
29. Giros B, Sokoloff P, Martres MP, et al: Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature 1989; 342:923-926
30. Semba J, Watanabe A, Kito S, et al: Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 1995; 34:785-791
31. Ben-Jonathan N, Hnasko R: Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001; 22:724-763
32. Aihara K, Shimada J, Miwa T, et al: The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res 2004; 1003:9-17
33. Burris KD, Molski TF, Xu C, et al: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302:381-389
34. Halbreich U, Kahn LS: Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract 2003; 9:344-353
35. Ataya K, Mercado A, Kartaginer J, et al: Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril 1988; 50:876-881
36. Halbreich U, Rojansky N, Palter S, et al: Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995; 57:485-491
37. Cabeza GA, Flores LF, Iñiguez IE, et al: Acute psychosis secondary to bromocriptine treatment in a patient with a prolactinoma. Rev Invest Clin 1984; 36:147-149
38. Peter SA, Autz A, Jean-Simon ML: Bromocriptine-induced schizophrenia. J Natl Med Assoc 1993; 85:700-701
39. Al-Semaan YM, Clay HA, Meltzer HY: Clozapine in treatment of bromocriptine-induced psychosis. J Clin Psychopharmacol 1997; 17:126-128